Blondy Sabrina, Durand Stéphanie, Lacroix Aurélie, Christou Niki, Bouchaud Charline, Peyny Maud, Battu Serge, Chauvanel Alain, Carré Vincent, Jauberteau Marie-Odile, Lalloué Fabrice, Mathonnet Muriel
Carcidiag Biotechnologies company, Guéret, France.
INSERM U1308 - CAPTuR "Control of cell activation, Tumor progression and Therapeutic resistance", Faculty of Medicine, University of Limoges, Limoges, France.
Front Oncol. 2022 Jul 22;12:918702. doi: 10.3389/fonc.2022.918702. eCollection 2022.
Nowadays, colon cancer prognosis still difficult to predict, especially in the early stages. Recurrences remain elevated, even in the early stages after curative surgery. Carcidiag Biotechnologies has developed an immunohistochemistry (IHC) kit called ColoSTEM Dx, based on a MIX of biotinylated plant lectins that specifically detects colon cancer stem cells (CSCs) through glycan patterns that they specifically (over)express. A retrospective clinical study was carried out on tumor tissues from 208 non-chemotherapeutic-treated and 21 chemotherapeutic-treated patients with colon cancer, which were stained by IHC with the MIX. Clinical performances of the kit were determined, and prognostic and predictive values were evaluated. With 78.3% and 70.6% of diagnostic sensitivity and specificity respectively, our kit shows great clinical performances. Moreover, patient prognosis is significantly poorer when the MIX staining is "High" compared to "Low", especially at 5-years of overall survival and for early stages. The ColoSTEM Dx kit allows an earlier and a more precise determination of patients' outcome. Thus, it affords an innovating clinical tool for predicting tumor aggressiveness earlier and determining prognosis value regarding therapeutic response in colon cancer patients.
如今，结肠癌的预后仍然难以预测，尤其是在早期阶段。即使在根治性手术后的早期阶段，复发率仍然居高不下。Carcidiag生物技术公司开发了一种名为ColoSTEM Dx的免疫组织化学（IHC）试剂盒，它基于生物素化植物凝集素的混合物，通过结肠癌干细胞（CSC）特异性（过度）表达的聚糖模式来特异性检测这些细胞。对208例未经化疗治疗和21例经化疗治疗的结肠癌患者的肿瘤组织进行了一项回顾性临床研究，这些组织用该混合物进行免疫组化染色。测定了该试剂盒的临床性能，并评估了其预后和预测价值。我们的试剂盒诊断敏感性和特异性分别为78.3%和70.6%，显示出良好的临床性能。此外，与“低”染色相比，当混合物染色为“高”时，患者预后明显较差，尤其是在总生存期5年时以及早期阶段。ColoSTEM Dx试剂盒能够更早、更精确地确定患者的预后。因此，它为更早地预测肿瘤侵袭性以及确定结肠癌患者治疗反应的预后价值提供了一种创新的临床工具。
